Non-Viral Vector Transfection Reagents Market Revenue to Cross USD 1.5 billion by 2035 | Roots Analysis

According to a recently published report by Roots Analysis, the growing demand for non-viral transfection products and rising interest of recombinant therapy developers is driving the non-viral vector transfection reagent and systems market growth

Non-Viral Transfection Reagent Industry Overview

The global non-viral transfection reagents market size was estimated at USD 633 million in 2023 and is expected to reach over USD 1.5 billion by 2035, growing at a CAGR of 8.0% during the forecast period 2023-2035.

Non-viral vectors, as the name suggests, do not use viral components for transfection and are aimed at circumventing the challenges, such as inflammation, immunogenicity and non-specific transduction, associated with viral vectors. Despite the fact that several reagents and products for efficient transfection have been researched and developed, the non-viral transfection reagents domain is continuously introducing the new in compounds being explored. The gene transfer to cells of interest may involve either direct introduction of naked DNA into the host cell, or the delivery of carrier gene with the help of complex formation with lipids, polymers or lipo-polymers. In both the cases, gene sequences are inserted into a plasmid (vector) for its expression within the host.  Due to low immunogenicity, non-viral transfection systems allow re-dosing of genetic material without the risk of complications. Moreover, such reagents are more economical than viral vectors as they can be easily produced in large quantities.

Browse 120+ figures and 140+ market data tables spread across 250+ pages and detailed Table of Content on “Non-viral Transfection Reagents Market by Type of Non-viral Transfection Method, End-User, Application Areas and Key Geographical Regions: Industry Trends and Global Forecasts, 2023-2035” here: https://www.rootsanalysis.com/reports/non viral-transfection/307.html

Market Drivers

Several factors are propelling the market size of non-viral transfection reagents. One such factor is the rising popularity of gene therapies for the treatment of patients suffering from oncological disorders. The growing demand for gene therapies ultimately drives the demand for novel non-viral transfection reagents and systems. Owing to the high safety profile of non-viral vectors, various gene therapies rely on the non-viral vector transfection reagent. Moreover, these reagents help in producing safer and more effective therapies. The growing need for non-viral vectors demands technological advanced technologies, which is anticipated to contribute to the market growth of novel non-viral vector transfection reagents and systems.

Market Restraints

Although the non-viral transfection reagents market is experiencing substantial growth, it is not without its challenges. Some of these challenges include use of home brew reagents by the researchers, selective effectiveness of transfection reagent and high cost of the transfection reagent.  In addition, to the afore-mentioned challenges, long approval procedures for non-viral transfection reagents is also hindering the  market growth. Regulatory guidelines for the approval of these products are quite strict and also requires continuous monitoring. To comply with the regulatory standards, the industry players have to investment a lot of amount to ensure proper effectiveness and safety of the non-viral transfection reagent products.

Growth Factors

Despite the challenges, several growth factors continue to drive the non-viral transfection reagents market forward. One notable factor is the exploration of emerging markets. Post making an impact in the developed nations, North American and European players have started penetrating the developing nations, such as China, India and other countries. The emerging nations allow these players to combat the losses that arise from the well-established markets. Given the opportunity associated within the emerging markets, the industry players are anticipated to expand their global presence resulting in the growing opportunity associated with the non-viral transfection reagents market.

Non-viral Transfection Reagents Market Segments

Based on the type of non-viral transfections method, the market is segmented into chemical methods, physical methods and other methods.

• The physical methods segment led the non-viral transfection reagents market, capturing the largest revenue share of close to 50.0% in 2023.
• The others segment is anticipated to show the highest growth potential by growing at a CAGR of around 10% annually, during the forecast period.

Based on the application area, the market is segmented into research applications and clinical applications.

• The research applications segment led the non-viral transfection reagents market, capturing the largest revenue share of close to 80.0% in 2023.
• The clinical applications segment is anticipated to show the highest growth potential by growing at a CAGR of over 9% annually, during the forecast period.

Based on the end-users, the market is segmented into pharmaceutical and biopharmaceutical players, academic and research institutes and other players.

• The academic and research institutes segment led the non-viral transfection reagents market, capturing the largest revenue share of more than 50.0% in 2023.
• The pharmaceutical and biopharmaceutical players segment is anticipated to show the highest growth potential by growing at a CAGR of close to 9% annually, during the forecast period.

Based on the Regional Insights, the market is segmented into North America, Europe, Asia Pacific and Rest of the World.

• North America dominated the non-viral transfection reagents market and accounted for the largest revenue share of over 40.0% in 2023.
• In Asia Pacific, the non-viral transfection reagents market is anticipated to demonstrate lucrative growth during the forecast period.

Key Companies Profiled

The non-viral transfection reagents market report also includes detailed profiles of key players (listed below) that offer non-viral transfection reagents and systems:

• Altogen Biosystems
• Bio-Rad Laboratories 
• BEX
• BTX
• Celsion 
• Genprex
• Inovio Pharmaceuticals
• MaxCyte
• MilliporeSigma
• Nepa Gene
• OZ Biosciences
• Thermo Fisher Scientific

You Can Download Free Sample PDF Copy of This Report at:
https://www.rootsanalysis.com/reports/non-viral-transfection/request-sample.html

About Roots Analysis

Roots Analysis is a global leader in the pharma / biotech market research. Having worked with over 750 clients worldwide, including Fortune 500 companies, start-ups, academia, venture capitalists and strategic investors for more than a decade, we offer a highly analytical / data-driven perspective to a network of over 450,000 senior industry stakeholders looking for credible market insights. All reports provided by us are structured in a way that enables the reader to develop a thorough perspective on the given subject. Apart from writing reports on identified areas, we provide bespoke research / consulting services dedicated to serve our clients in the best possible way.

Contact Details

Gaurav Chaudhary
Email: Gaurav.chaudhary@rootsanalysis.com or sales@rootsanalysis.com